NO20033299L - Nytt benzoylguanidinsalt, anvendelse av slike forbindelser som medikament samt anvendelse av slike forbindelser for fremstilling av farmasoytisk preparat for behandling av sykdommer - Google Patents
Nytt benzoylguanidinsalt, anvendelse av slike forbindelser som medikament samt anvendelse av slike forbindelser for fremstilling av farmasoytisk preparat for behandling av sykdommerInfo
- Publication number
- NO20033299L NO20033299L NO20033299A NO20033299A NO20033299L NO 20033299 L NO20033299 L NO 20033299L NO 20033299 A NO20033299 A NO 20033299A NO 20033299 A NO20033299 A NO 20033299A NO 20033299 L NO20033299 L NO 20033299L
- Authority
- NO
- Norway
- Prior art keywords
- compounds
- diseases
- medicaments
- preparation
- treatment
- Prior art date
Links
- AJDQRQQNNLZLPM-UHFFFAOYSA-N n-(diaminomethylidene)benzamide Chemical class NC(N)=NC(=O)C1=CC=CC=C1 AJDQRQQNNLZLPM-UHFFFAOYSA-N 0.000 title abstract 3
- 201000010099 disease Diseases 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 title 2
- 239000003814 drug Substances 0.000 title 1
- 239000000825 pharmaceutical preparation Substances 0.000 title 1
- 238000002360 preparation method Methods 0.000 title 1
- 150000004677 hydrates Chemical class 0.000 abstract 3
- 230000001413 cellular effect Effects 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- UFVMVHAWZDUFMJ-UHFFFAOYSA-N n-(diaminomethylidene)-4-[4-(1h-pyrrole-2-carbonyl)piperazin-1-yl]-3-(trifluoromethyl)benzamide;hydrochloride Chemical compound Cl.FC(F)(F)C1=CC(C(=O)NC(=N)N)=CC=C1N1CCN(C(=O)C=2NC=CC=2)CC1 UFVMVHAWZDUFMJ-UHFFFAOYSA-N 0.000 abstract 1
- 239000008194 pharmaceutical composition Chemical class 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/36—Oxygen or sulfur atoms
- C07D207/40—2,5-Pyrrolidine-diones
- C07D207/416—2,5-Pyrrolidine-diones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Dermatology (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10106970A DE10106970A1 (de) | 2001-02-15 | 2001-02-15 | Neues Benzoylguanidinsalz |
| PCT/EP2002/001535 WO2002064563A1 (de) | 2001-02-15 | 2002-02-14 | Neues benzoylguanidinsalz |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO20033299D0 NO20033299D0 (no) | 2003-07-22 |
| NO20033299L true NO20033299L (no) | 2003-07-22 |
Family
ID=7674094
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20033299A NO20033299L (no) | 2001-02-15 | 2003-07-22 | Nytt benzoylguanidinsalt, anvendelse av slike forbindelser som medikament samt anvendelse av slike forbindelser for fremstilling av farmasoytisk preparat for behandling av sykdommer |
Country Status (31)
| Country | Link |
|---|---|
| US (2) | US20080025919A1 (https=) |
| EP (1) | EP1362030B1 (https=) |
| JP (3) | JP4408626B2 (https=) |
| KR (1) | KR100862176B1 (https=) |
| CN (1) | CN1222510C (https=) |
| AT (1) | ATE553078T1 (https=) |
| AU (1) | AU2002250939B2 (https=) |
| BG (1) | BG66330B1 (https=) |
| BR (1) | BR0207867A (https=) |
| CA (1) | CA2434829C (https=) |
| CY (1) | CY1112878T1 (https=) |
| CZ (1) | CZ303277B6 (https=) |
| DE (1) | DE10106970A1 (https=) |
| DK (1) | DK1362030T3 (https=) |
| EA (1) | EA006245B1 (https=) |
| EC (1) | ECSP034708A (https=) |
| EE (1) | EE200300393A (https=) |
| ES (1) | ES2385472T3 (https=) |
| HR (1) | HRP20030653B1 (https=) |
| HU (1) | HU230035B1 (https=) |
| IL (1) | IL156934A (https=) |
| NO (1) | NO20033299L (https=) |
| NZ (1) | NZ528081A (https=) |
| PL (1) | PL213300B1 (https=) |
| PT (1) | PT1362030E (https=) |
| RS (1) | RS52014B (https=) |
| SI (1) | SI1362030T1 (https=) |
| SK (1) | SK287830B6 (https=) |
| UA (1) | UA74625C2 (https=) |
| WO (1) | WO2002064563A1 (https=) |
| ZA (1) | ZA200305365B (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10106970A1 (de) * | 2001-02-15 | 2002-08-29 | Boehringer Ingelheim Pharma | Neues Benzoylguanidinsalz |
| DE10144030A1 (de) * | 2001-09-07 | 2003-03-27 | Boehringer Ingelheim Pharma | Verbesserung der lokalen Verträglichkeit bei intravenöser Verabreichung von 4-(4-(2-Pyrrolylcarbonyl-1-piperazinyl)-3-trifluormethyl-benzoylguanidin |
| US6982256B2 (en) | 2001-09-07 | 2006-01-03 | Boehringer Ingelheim Pharma Kg | Tolerance of 4-(4-(2-pyrrolylcarbonyl)-1-piperazinyl)-3-trifluoromethyl-benzoylguanidine in intravenous administration |
| CA2730116A1 (en) * | 2008-07-08 | 2010-01-14 | Boehringer Ingelheim International Gmbh | Pyrrolidinyl and piperidinyl compounds useful as nhe-1 inhibitors |
| US10405746B2 (en) * | 2014-04-14 | 2019-09-10 | The University Of Memphis Research Foundation | Wireless analog passive sensors |
| US12369831B1 (en) | 2018-04-30 | 2025-07-29 | Bashir I. Morshed | Apparatus and method to capture body signals with conjugate coils and paired coils |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19601303A1 (de) * | 1996-01-16 | 1997-07-17 | Boehringer Ingelheim Kg | Neuartige Benzoylguanidin-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung bei der Herstellung von Arzneimitteln |
| US6323207B1 (en) * | 1998-09-22 | 2001-11-27 | Boehringer Ingelheim Pharma Kg | Benzoylguanidine derivatives |
| DE19843489B4 (de) * | 1998-09-22 | 2006-12-21 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Benzoylguanidin-Abkömmlinge mit vorteilhaften Eigenschaften, Verfahren zu ihrer Herstellung und ihre Verwendung bei der Herstellung von Arzneimitteln, sowie diese enthaltende pharmazeutische Zubereitung |
| US6730678B2 (en) * | 2001-02-15 | 2004-05-04 | Boehringer Ingelheim Pharma Kg | Benzoylguanidine salt and hydrates thereof |
| DE10106970A1 (de) * | 2001-02-15 | 2002-08-29 | Boehringer Ingelheim Pharma | Neues Benzoylguanidinsalz |
-
2001
- 2001-02-15 DE DE10106970A patent/DE10106970A1/de not_active Ceased
-
2002
- 2002-02-14 BR BR0207867-8A patent/BR0207867A/pt not_active Application Discontinuation
- 2002-02-14 PL PL362129A patent/PL213300B1/pl unknown
- 2002-02-14 HU HU0303027A patent/HU230035B1/hu not_active IP Right Cessation
- 2002-02-14 DK DK02719831.6T patent/DK1362030T3/da active
- 2002-02-14 WO PCT/EP2002/001535 patent/WO2002064563A1/de not_active Ceased
- 2002-02-14 CZ CZ20032210A patent/CZ303277B6/cs not_active IP Right Cessation
- 2002-02-14 AU AU2002250939A patent/AU2002250939B2/en not_active Ceased
- 2002-02-14 EP EP02719831A patent/EP1362030B1/de not_active Expired - Lifetime
- 2002-02-14 AT AT02719831T patent/ATE553078T1/de active
- 2002-02-14 HR HRP20030653AA patent/HRP20030653B1/xx not_active IP Right Cessation
- 2002-02-14 SK SK1020-2003A patent/SK287830B6/sk not_active IP Right Cessation
- 2002-02-14 ES ES02719831T patent/ES2385472T3/es not_active Expired - Lifetime
- 2002-02-14 JP JP2002564496A patent/JP4408626B2/ja not_active Expired - Fee Related
- 2002-02-14 CA CA002434829A patent/CA2434829C/en not_active Expired - Fee Related
- 2002-02-14 CN CNB028049926A patent/CN1222510C/zh not_active Expired - Fee Related
- 2002-02-14 KR KR1020037010723A patent/KR100862176B1/ko not_active Expired - Fee Related
- 2002-02-14 EA EA200300771A patent/EA006245B1/ru not_active IP Right Cessation
- 2002-02-14 UA UA2003098454A patent/UA74625C2/uk unknown
- 2002-02-14 NZ NZ528081A patent/NZ528081A/en not_active IP Right Cessation
- 2002-02-14 SI SI200230982T patent/SI1362030T1/sl unknown
- 2002-02-14 RS YU61503A patent/RS52014B/sr unknown
- 2002-02-14 PT PT02719831T patent/PT1362030E/pt unknown
- 2002-02-14 EE EEP200300393A patent/EE200300393A/xx unknown
- 2002-02-14 IL IL15693402A patent/IL156934A/en not_active IP Right Cessation
-
2003
- 2003-07-11 ZA ZA200305365A patent/ZA200305365B/en unknown
- 2003-07-22 NO NO20033299A patent/NO20033299L/no not_active Application Discontinuation
- 2003-07-29 EC EC2003004708A patent/ECSP034708A/es unknown
- 2003-08-06 BG BG108065A patent/BG66330B1/bg unknown
-
2007
- 2007-08-21 US US11/842,941 patent/US20080025919A1/en not_active Abandoned
-
2008
- 2008-06-06 US US12/134,245 patent/US20080241077A1/en not_active Abandoned
-
2009
- 2009-07-15 JP JP2009166773A patent/JP5745215B2/ja not_active Expired - Fee Related
-
2012
- 2012-07-06 CY CY20121100605T patent/CY1112878T1/el unknown
-
2013
- 2013-03-08 JP JP2013047091A patent/JP2013107906A/ja not_active Withdrawn
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO5271691A1 (es) | Nuevos compuestos | |
| IL165264A (en) | Protein kinase inhibitors, pharmaceutical compositions comprising them and use thereof in the preparation of medicaments for treating protein kinase-associated diseases | |
| NO20021328L (no) | Pyrazolopyrimidier som terapeutiske midler | |
| BRPI0312464B8 (pt) | compostos inibidores de tirosina quinases, composições farmacêuticas compreendendo os mesmos, processos para fabricação e usos dos mesmos | |
| NO20041041L (no) | Fenetanolaminderivater for behandling av respiratoriske sykdommer | |
| NO20025601L (no) | Arylmetylaminderivater for anvendelse som tryptaseinhibitorer | |
| NO20081482L (no) | Delta- og epsilon-krystallformer for imatinibmesylat | |
| NO20030381L (no) | Bicyklopyrazoler som er aktive som kinaseinhibitorer, fremgangsmåte for deres fremstilling og farmasöytiske preparater som inneholder slikeforbindelser | |
| EE200300475A (et) | Türosiini kinaasi inhibiitorid, neid sisaldavad ravimkoostised ja nimetatud ühendid kasutamiseks haiguste ravis | |
| NO20051695L (no) | Nye spirokondenserte kinazolinoner og deres anvendelse som fosfodiestereaseinbibitorer | |
| SE0104340D0 (sv) | New compounds | |
| NO20055496D0 (no) | Pyrazolokinazolinderivater, metoder for deres fremstilling og deres anvendelse som kinaseinhibitorer | |
| IS6520A (is) | Ný efnasambönd | |
| SE9904176D0 (sv) | New use | |
| BR0309342A (pt) | Composto, composição farmacêutica, uso de um composto, e, método de tratamento ou profilaxia de doenças ou condições humanas | |
| GB0112348D0 (en) | Compounds | |
| MXPA04004601A (es) | Derivados de sulfonamidas, su preparacion y su aplicacion como medicamentos. | |
| AU2002314914A1 (en) | Hydroxy alkyl amine derivatives as beta-secretase inhibitors and their use for the treatment of alzheimer's disease and similar diseases | |
| NO20085271L (no) | Muscarin reseptoragonister som er effektive i behandling av smerte, Alzheimers sykdom og schizofreni | |
| BR9807950A (pt) | Composto, composição farmacêutica, uso de um composto, e, processos para tratar ou reduzir o risco de doenças ou condições humanas, o risco de doença inflamatória o risco da dor e para a preparação de um composto | |
| BR0316458A (pt) | Composto, composição farmacêutica, método de tratamento ou prevenção de doenças, método para intensificar a cognição em um paciente saudável, e, uso de um composto | |
| DK1641454T3 (da) | Pyrazolo[3,4-B]pyridin-6-oner som GSK-3-hæmmere | |
| SE0102440D0 (sv) | New compound | |
| NO20033299L (no) | Nytt benzoylguanidinsalt, anvendelse av slike forbindelser som medikament samt anvendelse av slike forbindelser for fremstilling av farmasoytisk preparat for behandling av sykdommer | |
| MXPA04005809A (es) | Inhibidores de proteinas quinasas. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |